Rituximab in immune thrombocytopenia: Transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients

International Journal of Hematology

Volumn 92, Issue 2, 2010, Pages 283-288

  Aleem, Aamer ^a   Alaskar, Ahmed S ^b   Algahtani, Farja ^a   Rather, Mushtaq ^b   Almahayni, Muhamad Hitham ^a   Al Momen, Abdulkarim ^a  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Adults; Immune thrombocytopenia; ITP; Platelets; Rituximab

Indexed keywords

AZATHIOPRINE; DANAZOL; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; RITUXIMAB; ROMIPLOSTIM; STEROID; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG ERUPTION; DRUG FEVER; FEMALE; FOLLOW UP; HEART PALPITATION; HUMAN; HYPOTENSION; IMMUNE THROMBOCYTOPENIA; MALE; REFRACTORY THROMBOCYTOPENIA; RELAPSE; REMISSION; SPLENECTOMY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956897382     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0635-4     Document Type: Article

References (35)

1. DB Cines V Blanchette 2002 Idiopathic thrombocytopenic purpura N Engl J Med 364 995 1008 10.1056/NEJMra010501 (Pubitemid 34983251)
2. DB Cines JB Bussel 2005 How I treat idiopathic thrombocytopenic purpura (ITP) Blood 106 7 2244 2251 10.1182/blood-2004-12-4598 15941913 1:CAS:528:DC%2BD2MXhtVKqt77K (Pubitemid 41510792)
3. R Simanek S Panzer K Lechner I Pabinger 2007 Late spontaneous remissions in severe adult autoimmune thrombocytopenia Ann Hematol 86 705 710 10.1007/s00277-007-0309-3 17503045 1:STN:280:DC%2BD2svptlOitg%3D%3D (Pubitemid 47337932)
4. YC Cohen B Djulbegovic O Shamai-Lubovitz B Mozes 2000 The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts Arch Intern Med 160 1630 1638 10.1001/archinte.160.11.1630 10847256 1:STN:280:DC%2BD3czgtlyluw%3D%3D
5. R McMillan 1997 Therapy for adults with refractory chronic autoimmune thrombocytopenic purpura Ann Int Med. 126 307 314 9036803 1:CAS:528: DyaK2sXhsFCnu7Y%3D
6. R Stasi E Stipa M Masi M Cecconi MT Scimò F Oliva A Sciarra AP Perrotti G Adomo S Amadori, et al. 1995 Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura Am J Med 98 436 442 10.1016/S0002-9343(99)80342-8 7733121 1:STN:280:DyaK2M3ltVOqtw%3D%3D
7. VJ Picozzi WR Roeske WP Creger 1980 Fate of therapy failure in adult idiopathic thrombocytopenic purpura Am J Med 69 690 694 10.1016/0002-9343(80) 90419-2 7192052 1:STN:280:DyaL3M%2FlvFKisQ%3D%3D (Pubitemid 11241344)
8. RS Cvetkovic CM Perry 2006 Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia Drugs. 66 791 820 10.2165/00003495-200666060-00005 16706552 1:CAS:528:DC%2BD28XlvF2jsLw%3D (Pubitemid 43778729)
9. N Di Gaetano E Cittera R Nota A Vecchi V Grieco E Scanziani M Botto M Introna J Golay 2003 Complement activation determines the therapeutic activity of rituximab in vivo J Immunol 171 1581 1587 12874252 1:CAS:528: DC%2BD3sXlsFylu7g%3D
10. J Golay R Gramigna V Facchinetti D Capello G Gaidano M Introna 2002 Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab Br J Haematol 119 923 929 10.1046/j.1365-2141.2002. 03935.x 12472569 1:CAS:528:DC%2BD3sXnt12ntw%3D%3D (Pubitemid 35463815)
11. T Robak 2004 Monoclonal antibodies in the treatment of autoimmune cytopenias Eur J Haematol 72 79 88 10.1046/j.0902-4441.2003.00196.x 14962245 1:CAS:528:DC%2BD2cXhslKrsrY%3D (Pubitemid 38161156)
12. R Stasi E Stipa V Forte P Meo S Amadori 2002 Variable pattern of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura Blood 99 3872 3873 10.1182/blood-2002-02-0392 12014370 1:CAS:528:DC%2BD38XjvVGms7k%3D (Pubitemid 34534570)
13. M Zecca B Nobili U Rameghi S Perrotta G Amendola P Rosito M Jankovic P Pierani P De Stefano MR Bonora F Locatelli 2003 Rituximab for the treatment of refractory autoimmune hemolytic anemia in children Blood 101 3857 3861 10.1182/blood-2002-11-3547 12531800 1:CAS:528:DC%2BD3sXktVGntL0%3D (Pubitemid 36857857)
14. MJ Leandro G Cambridge JC Edwards MR Ehrenstein DA Isenberg 2005 B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients Rheumatology (Oxford) 44 1542 1545 10.1093/rheumatology/kei080 1:CAS:528:DC%2BD2MXht1GltrzP (Pubitemid 41742472)
15. JC Edwards L Szczepanski J Szechinski A Filipowicz-Sosnowska P Emery DR Close RM Stevens T Shaw 2004 Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2572 2581 10.1056/NEJMoa032534 15201414 1:CAS:528:DC%2BD2cXkvFKntrc%3D (Pubitemid 38758544)
16. M Franchini D Veneri G Lippi R Stenner 2006 The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders Thromb Haemost 96 2 119 125 16894452 1:CAS:528:DC%2BD28Xpt1Shsrk%3D
17. E Kimby 2005 Tolerability and safety of rituximab (MabThera) Cancer Treat Rev 31 456 473 10.1016/j.ctrv.2005.05.007 16054760 1:CAS:528:DC%2BD2MXhtFKnu7vJ (Pubitemid 41536169)
18. R Stasi A Pagano E Stipa S Amadori 2001 Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura Blood 98 4 952 957 10.1182/blood.V98.4.952 11493438 1:CAS:528:DC%2BD3MXmtFeis70%3D
19. AA Giagounidis J Anhuf P Schneider U Germing D Söhngen K Quabeck C Aul 2002 Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study Eur J Haematol 69 2 95 100 10.1034/j.1600-0609.2002.02686.x 12366712 1:CAS:528:DC%2BD38XoslSru7g%3D (Pubitemid 35178108)
20. N Cooper R Stasi S Cunningham-Rundles MA Feuerstein JP Leonard S Amadori JB Bussel 2004 The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura Br J Haematol 125 2 232 239 10.1111/j.1365-2141.2004.04889.x 15059147 1:CAS:528:DC%2BD2cXktlKrsLk%3D (Pubitemid 38534976)
21. F Zaja N Vianelli M Battista A Sperotto F Patriarca V Tomadini C Filì M Tani M Baccarani R Fanin 2006 Earlier administration of rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia Exp Hematol 34 571 572 10.1016/j.exphem.2006.02.009 16647558 1:CAS:528:DC%2BD28XjvVGhtbc%3D
22. J Garcia-Chavez A Majluf-Cruz L Montiel-Cervantes MG-R Esparza J Vela-Ojeda Mexican Hematology Study Group 2007 Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis Ann Hematol 86 871 877 10.1007/s00277-007-0317-3 17874322 1:CAS:528: DC%2BD2sXht1ahu7fL
23. DM Arnold F Dentali MA Crowther RM Meyer RJ Cook C Sigouin GA Fraser W Lim JG Kelton 2007 Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura Ann Intern Med 146 25 33 17200219
24. FJ Peñalver V Jiménez-Yuste M Almagro A Alvarez- Larrán L Rodríguez M Casado L Gallur P Giraldo R Hernández D Menor MJ Rodríguez D Caballero R González J Mayans I Millán JR Cabrera Multi-institutional Retrospective Spanish Study Group on the use of rituximab in refractory ITP 2006 Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients Ann Hematol 85 6 400 406 10.1007/s00277-005- 0073-1 16550390 1:CAS:528:DC%2BD28Xjs1KksLo%3D
25. P Braendstrup OW Bjerrum OJ Nielsen BA Jensen NT Clausen PB Hansen I Andersen K Schmidt TM Andersen NA Peterslund HS Birgens T Plesner BB Pedersen HC Hasselbalch 2005 Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura Am J Hematol 78 4 275 280 10.1002/ajh.20276 15795920 1:CAS:528:DC%2BD2MXktVSisrk%3D (Pubitemid 40471119)
26. C Schweizer FJ Reu AD Ho M Hensel 2007 Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab Ann Hematol 86 10 711 717 10.1007/s00277-007-0335-1 17622529 1:CAS:528:DC%2BD2sXpsVejsL0%3D (Pubitemid 47337933)
27. DB Cines JB Bussel HA Liebman ET Luning Prak 2009 The ITP syndrome: pathogenic and clinical diversity Blood 113 26 6511 6521 10.1182/blood-2009-01- 129155 19395674 1:CAS:528:DC%2BD1MXotlWrur0%3D
28. M Ruggeri S Fortuna F Rodeghiero 2008 Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature Haematologica. 93 98 103 10.3324/haematol.11582 18166791 (Pubitemid 351156157)
29. B Godeau R Porcher O Fain F Lefrère P Fenaux S Cheze A Vekhoff MP Chauveheid J Stirnemann L Galicier E Bourgeois S Haiat B Varet M Leporrier T Papo M Khellaf M Michel P Bierling 2008 Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study Blood 112 999 1004 10.1182/blood-2008- 01-131029 18463354 1:CAS:528:DC%2BD1cXpvVOksLw%3D
30. F Zaja N Vianelli A Sperotto S De Vita I Iacona A Zaccaria P Masolini V Tomadini M Tani AL Molinari M Baccarani R Fanin 2003 B-cell compartment as the selective target for the treatment of immune thrombocytopenias Haematologica 88 5 538 546 12745273
31. D Dierickx G Verhoef A Van Hoof P Mineur A Roest A Triffet A Kentos P Pierre D Boulet G Bries PQ Lê A Janssens A Delannoy 2009 Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study J Intern Med 266 5 484 491 10.1111/j.1365-2796. 2009.02126.x 19549092 1:CAS:528:DC%2BD1MXhsVyisbjL
32. R Stasi G Del Poeta E Stipa ML Evangelista MM Trawinska N Cooper S Amadori 2007 Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura Blood 110 2924 2930 10.1182/blood-2007-02-068999 17548576 1:CAS:528:DC%2BD2sXht1Smu77J (Pubitemid 350006946)
33. TE Warkentin DM Arnold 2008 "Spare-spleen-uximab" for chronic ITP Blood 112 4 925 926 10.1182/blood-2008-06-159335 18684872 1:CAS:528:DC%2BD1cXpvVOksrk%3D
34. TH Oo 2005 Rituximab is effective in the treatment of refractory immune thrombocytopenic purpura associated with chronic lymphocytic leukemia South Med J 98 12 1227 1228 10.1097/01.smj.0000190101.56301.a2 16440930 (Pubitemid 43068366)
35. F Zaja N Vianelli A Sperotto F Patriarca M Tani L Marin M Tiribelli A Candoni M Baccarani R Fanin 2003 Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases Leuk Lymphoma 44 11 1951 1955 10.1080/1042819031000119235 14738149 1:CAS:528:DC%2BD3sXns1Grtbs%3D (Pubitemid 37369630)